Open Label Multi-Centric Phase II Study of the Raf Kinase Inhibitor BAY 43-9006 in Chronic Myelogenous Leukemia (CML) Patients Resistant to Gleevec (Imatinib)
Phase of Trial: Phase II
Latest Information Update: 02 Jan 2015
At a glance
- Drugs Sorafenib (Primary)
- Indications Chronic myeloid leukaemia
- Focus Therapeutic Use
- Acronyms ORACLE
- Sponsors Bayer
- 07 Jun 2017 Biomarkers information updated
- 07 May 2008 The expected completion date for this trial is now .
- 15 Apr 2008 Status changed from in progress to completed according to ClinicalTrials.gov.